Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have been given an average recommendation of “Moderate Buy” by the twelve ratings firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $324.1111.

A number of brokerages recently weighed in on KRYS. Guggenheim raised their price target on shares of Krystal Biotech from $224.00 to $284.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Chardan Capital raised their price target on shares of Krystal Biotech from $220.00 to $323.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Wolfe Research began coverage on shares of Krystal Biotech in a research note on Friday, March 27th. They issued a “peer perform” rating on the stock. Jefferies Financial Group raised their price target on shares of Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Finally, Evercore reaffirmed an “outperform” rating and issued a $300.00 price target on shares of Krystal Biotech in a research note on Tuesday, May 5th.

Krystal Biotech Price Performance

NASDAQ:KRYS opened at $317.97 on Wednesday. Krystal Biotech has a 52 week low of $127.99 and a 52 week high of $331.49. The stock has a market capitalization of $9.37 billion, a PE ratio of 42.51 and a beta of 0.53. The stock’s 50-day moving average price is $288.44 and its 200-day moving average price is $268.27.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. The firm had revenue of $116.36 million for the quarter, compared to analysts’ expectations of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. Sell-side analysts expect that Krystal Biotech will post 7.83 earnings per share for the current fiscal year.

Insider Transactions at Krystal Biotech

In related news, EVP John Charles Thomas sold 642 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $302.03, for a total value of $193,903.26. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the transaction, the insider directly owned 1,378,155 shares in the company, valued at $424,623,337.05. This represents a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bessemer Group Inc. boosted its holdings in shares of Krystal Biotech by 106.9% during the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock worth $26,000 after purchasing an additional 77 shares during the last quarter. Sound Income Strategies LLC boosted its holdings in shares of Krystal Biotech by 1,270.0% during the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after purchasing an additional 127 shares during the last quarter. Western Wealth Management LLC acquired a new position in shares of Krystal Biotech during the 1st quarter worth approximately $34,000. Greenline Wealth Management LLC acquired a new position in shares of Krystal Biotech during the 4th quarter worth approximately $34,000. Finally, Danske Bank A S acquired a new position in shares of Krystal Biotech during the 3rd quarter worth approximately $35,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.